Stockscreener 앱 받기
9.97
2.06%
-0.21
시간 외 거래:
10.00
0.03
+0.30%
전일 마감가:
$10.18
열려 있는:
$10.28
하루 거래량:
138.44K
Relative Volume:
0.79
시가총액:
$143.79M
수익:
$6.39M
순이익/손실:
$-117.26M
주가수익비율:
-0.7988
EPS:
-12.4807
순현금흐름:
$-79.08M
1주 성능:
-13.00%
1개월 성능:
-30.72%
6개월 성능:
+60.29%
1년 성능:
-34.02%
1일 변동 폭
$9.70
$10.71
1주일 범위
$9.70
$11.56
52주 변동 폭
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
명칭
Korro Bio Inc
전화
617-468-1999
주소
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
9.97 | 146.82M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2026-02-17 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2026-01-29 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2026-01-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2026-01-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-01-28 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-11-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Raymond James | Strong Buy |
| 2024-08-14 | 개시 | William Blair | Outperform |
| 2024-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2024-02-27 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-04 | 개시 | H.C. Wainwright | Buy |
| 2023-11-29 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-10 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-01-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-10-28 | 개시 | Cowen | Outperform |
| 2019-10-28 | 개시 | Goldman | Buy |
| 2019-10-28 | 개시 | JP Morgan | Overweight |
모두보기
Korro Bio Inc 주식(KRRO)의 최신 뉴스
Citi Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $21 - Moomoo
Citigroup Initiates Korro Bio at Buy With $21 Price Target - marketscreener.com
Lynx1 Capital Management LP's Korro Bio Inc(KRRO) Holding History - GuruFocus
Should You Sell Korro Bio (KRRO) After -8.12% Drop? 2026-05-15Cash Flow - newser.com
Korro Bio, Inc. advances KRRO-121 RNA editing therapy for hyperammonemia toward clinical stage - Traders Union
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Korro Bio hire gets option for 3,000 shares at $11.20 - Stock Titan
Korro Bio, Inc.Common Stock (NQ: KRRO - The Chronicle-Journal
Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN
Korro announces oversubscribed $85 million private placement - MSN
Number of shareholders of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
Korro Bio (NASDAQ:KRRO) Announces Quarterly Earnings Results - MarketBeat
Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus
JonesTrading Upgrades Korro Bio(KRRO.US) to Buy Rating, Announces Target Price $23 - Moomoo
Jones Trading upgrades Korro Bio stock rating on AATD program potential By Investing.com - Investing.com South Africa
Jones Trading upgrades Korro Bio stock rating on AATD program potential - Investing.com Nigeria
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Korro Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korro Bio IncReports No Collaboration Reve - Moomoo
Korro Bio (KRRO) trims R&D spend and boosts cash to $157M - Stock Titan
Korro Bio, Inc. 1Q 2026: Revenue $0M, EPS $(1.69) — 10-Q Summary - TradingView
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Korro raises $85M, targets 2026 filing for rare-disease drug - Stock Titan
Korro Bio (Nasdaq: KRRO) boosts cash to $157M and targets 2026 KRRO-121 filing - Stock Titan
What Korro Bio (KRRO) management is not saying enough about (Technical Strength) 2026-05-06Top Trending Breakouts - newser.com
Korro CEO and top executives line up two investor fireside chats - Stock Titan
Korro to Participate in Upcoming Investor Conferences - marketscreener.com
Korro Bio Inc expected to post a loss of $1.84 a shareEarnings Preview - TradingView
What makes Korro Bio, Inc. (KRRO) a new buy stock - MSN
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock - Yahoo Finance Australia
Raymond James upgrades Korro Bio (KRRO) - MSN
Korro Bio (KRRO) Moat Analysis | Q4 2025: Earnings Beat EstimatesExpert Momentum Signals - Cổng thông tin điện tử tỉnh Lào Cai
KRRO (Korro Bio Inc.) reports smaller than projected Q4 2025 loss, shares rise nearly 7 percent on investor optimism.Hot Market Picks - newser.com
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences - The Manila Times
Korro brings ammonia and liver disease data to 4 spring conferences - Stock Titan
[ARS] Korro Bio, Inc. SEC Filing - Stock Titan
Korro Bio (KRRO) outlines 2026 virtual meeting, director elections and pay vote - Stock Titan
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule - National Today
Latest KRRO NewsKorro to Present at the 42nd Annual J.P. Mo... - Stock Titan
Korro Bio reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Korro Bio hire gets stock option for 15,000 shares under Nasdaq rule - Stock Titan
Block Trades: Does Korro Bio Inc have pricing powerWeekly Investment Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Lynx1 Capital Management LP Increases Stake in Korro Bio Inc - GuruFocus
Korro Bio Inc (KRRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.53%
자본화:
|
볼륨(24시간):